Circumvention of cytarabine (Ara-C) resistance by 2-chloro-deoxyadenosine (2-CdA) in pediatric acute myeloid (AML) and acute lymphoblastic (ALL) leukemia: An in vitro study.

被引：0
|
作者：
Zwaan, CM
Kaspers, GJL
Pieters, R
Huismans, DR
Van Wering, ER
Janka-Schaub, GE
Creutzig, U
Henze, G
Veerman, AJP
机构：
[1] Vrije Univ Amsterdam, Univ Hosp Amsterdam, Dept Pediat Hematol Oncol, Amsterdam, Netherlands
[2] Sophia Childrens Hosp, Dept Hematol Oncol, Rotterdam, Netherlands
[3] Dutch Childhood Leukemia Study Grp, The Hague, Netherlands
[4] CoALL Study Grp, Hamburg, Germany
[5] AML BFM Study Grp, Munster, Germany
[6] BFM ALL Relapse Study Grp, Berlin, Germany
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1327
引用
收藏
页码：307A / 307A
页数：1
相关论文
共 50 条
  • [21] Clofarabine and clofarabine plus low-dose cytarabine (ara-C) as induction therapy for patients (pts) ≥ 60 years with newly diagnosed acute myeloid leukemia (AML)
    Faderl, S
    Ravandi, F
    Ferrajoli, A
    Garcia-Manero, G
    Estrov, Z
    Thomas, DA
    O'Brien, S
    Verstovsek, S
    Wierda, W
    Cortes, J
    Giles, FJ
    Kwari, M
    Jarmon, R
    Kantarjian, HM
    BLOOD, 2005, 106 (11) : 786A - 786A
  • [22] Mylotarg, fludarabine, cytarabine (Ara-C) and cyclosporine (MFAC) combination regimen in patients with CD33-positive primary resistant or relapsed acute myeloid leukemia (AML).
    Tsimberidou, AM
    Estey, E
    Cortes, J
    Thomas, D
    Garcia-Manero, G
    Faderl, S
    Verstovesk, S
    O'Brien, S
    Kantarjian, H
    Giles, F
    BLOOD, 2002, 100 (11) : 339A - 340A
  • [23] Epigenetic action of decitabine (5-aza-2′-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C)
    Momparler, Richard L.
    Cote, Sylvie
    Momparler, Louise F.
    LEUKEMIA RESEARCH, 2013, 37 (08) : 980 - 984
  • [24] USE OF STROMA-SUPPORTED CULTURES OF LEUKEMIC-CELLS TO ASSESS ANTILEUKEMIC DRUGS .2. POTENT CYTOTOXICITY OF 2-CHLORO-DEOXYADENOSINE IN ACUTE LYMPHOBLASTIC-LEUKEMIA
    KUMAGAI, M
    MANABE, A
    COUSTANSMITH, E
    BLAKLEY, RL
    BECK, WT
    SANTANA, VM
    BEHM, FG
    RAIMONDI, SC
    CAMPANA, D
    LEUKEMIA, 1994, 8 (07) : 1116 - 1123
  • [25] Phase I study of UCN-01 and ara-C for patients with refractory or relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Cortes, J
    Plunkett, WK
    Estey, EH
    Keating, MJ
    Madden, T
    Sampath, D
    Faderl, S
    Beran, M
    Dancey, J
    Kantarjian, HM
    BLOOD, 2001, 98 (11) : 211B - 211B
  • [26] Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias
    Faderl, S
    Gandhi, V
    O'Brien, S
    Bonate, P
    Cortes, J
    Estey, E
    Beran, M
    Wierda, W
    Garcia-Manero, G
    Ferrajoli, A
    Estrov, Z
    Giles, FJ
    Du, M
    Kwari, M
    Keating, M
    Plunkett, W
    Kantarjian, H
    BLOOD, 2005, 105 (03) : 940 - 947
  • [27] A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression
    Al-Kali, Aref
    Tibes, Raoul
    Atherton, Pamela
    Palmer, Jeanne
    Alkhateeb, Hassan B. B.
    Patnaik, Mrinal
    Begna, Kebede
    Gangat, Naseema
    Hashmi, Shahrukh
    He, Rong
    Litzow, Mark
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (03) : 472 - 480
  • [28] Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C
    Cheng, Cong
    Yuan, Fang
    Chen, Xiao-Ping
    Zhang, Wei
    Zhao, Xie-Lan
    Jiang, Zhi-Ping
    Zhou, Hong-Hao
    Zhou, Gan
    Cao, Shan
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 142
  • [29] Idarubicin/Ara-C (IDAC) vs mitoxantrone/etoposide (MIET) as primary chemotherapy in a sequential induction regimen for de novo acute myeloid leukemia (AML): A randomized clinical study.
    Bernasconi, C
    Lazzarino, M
    Pagnucco, G
    Canevari, A
    Castelli, G
    Alessandrino, EP
    Brusamolino, E
    Castagnola, C
    Bernasconi, P
    Bonfichi, M
    Orlandi, E
    BLOOD, 1998, 92 (10) : 232A - 232A
  • [30] A Phase I Combination Study of Ribavirin and Low Dose Cytarabine Arabinoside (ara-C) in M4/M5 Acute Myeloid Leukemia (AML) and AML with High eIF4E
    Assouline, Sarit
    Kraljacic-Culjkovic, Biljana
    Cocolakis, Eftihia
    Amri, Abdellatif
    Bergeron, Julie
    Jamal, Rahima
    Miller, Wilson H., Jr.
    Borden, Katherine L. B.
    BLOOD, 2011, 118 (21) : 1540 - 1540
12345